|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparative study of minimally invasive versus open esophagectomy for esophageal cancer in a single cancer center显示文摘 | Mu Juwei Yuan Zuyang Zhang Baihua Li Ning Lyu Fang Mao Yousheng Xue Qi Gao Shugeng Zhao Jun Wang Dali Li Zhishan Gao Yushun Zhang Liangze Huang Jinfeng Shao Kang Feng Feiyue Zhao Liang Li Jian Cheng Guiyu Sun Kelin He Jie | 2014 | Chinese Medical Journal2014，，4： | 13 |
| 2 | An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma显示文摘No clinically available biomarkers can predict pathological complete response(pCR)for esophageal squamous cell carcinomas(ESCCs)with neoadjuvant chemoradiotherapy(nCRT).Considering that antitumor immunity status is an important determinant for nCRT,we performed an integrative analysis of immune-related gene profiles from pretreatment biopsies and constructed the first individualized immune signature for pCR and outcome prediction of ESCCs through a multicenter analysis.During the discovery phase,14 differentially expressed immune-related genes(DEIGs)with greater than a twofold change between pCRs and less than pCRs( | Chaoqi Zhang Guochao Zhang Nan Sun Zhen Zhang Liyan Xue Zhihui Zhang Haijun Yang Yuejun Luo Xiaoli Zheng Yonglei Zhang Yufen Yuan Ruixue Lei Zhaoyang Yang Bo Zheng Le Wang Yun Che Feng Wang Sihui Wang Shugeng Gao Qi Xue Yi Zhang Jie He | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 7 |
| 3 | Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?显示文摘Esophageal cancer(EC)is a common cancer and is histopathologically classified into esophageal squamous cell carcinoma and esophageal adenocarcinoma.EC is a worldwide public health issue because of late diagnosis and lack of effective therapy.In contrast to standard tumor biopsies,liquid biopsies are emerging as a tool which is minimally invasive that can complement or even substitute more classical approaches.Specifically,cell-free DNA(cfDNA)has shown promise in cancer-related clinical applications.Indeed,cfDNA has been shown to be an effective circulating biomarker for non-invasive cancer diagnosis and monitoring of cancer patients.Although the clinical application of cfDNA has been reported on other cancers,few studies have evaluated its use in EC.Here,we review this relevant literature and discuss limitations and advantages of its application in the diagnosis and monitoring of EC. | Zuyang Yuan Xinfeng Wang Xiao Geng Yin Li Juwei Mu Fengwei Tan Qi Xue Shugeng Gao Jie He | 2021 | Cancer Communications2021，41，1： | 4 |
| 4 | Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis:a TCGA pan-cancer analysis显示文摘Background:Cancer cells reprogram metabolism for proliferation.Phosphoglycerate kinase 1(PGK1),as a glycolytic enzyme and newly identified protein kinase,coordinates glycolysis and mitochondrial metabolism.However,the clini-cal significance of PGK1 expression and function in cancer progression is unclear.Here,we investigated the relation-ship between the progression and prognosis of multiple cancer types and PGK1 expression and its function in the mitochondrial metabolism regulation.Methods:We performed pan-cancer analyses of PGK1 mRNA level and DNA methylation in 11,908 tumor tissues and 1582 paired normal tissues across 34 cancer types in The Cancer Genome Atlas datasets.Using specific antibodies against PGK1 S203 and PDHK1 T338 phosphorylation,we performed immunohistochemistry with tissue microarray assay in additional 818 cancer cases with 619 paired normal tissues from five cancer types.Results:The PGK1 mRNA level was significantly elevated with hypomethylation in promotor regions and associated with advanced TNM stage in 15 and four cancer types,respectively.In breast carcinoma,elevated PGK1 mRNA level and promoter hypomethylation were associated with poor prognosis.Positively correlated PGK1 S203 and PDHK1 T338 phosphorylation levels were significantly associated with short overall survival(OS)in cancers of the breast,liver,lung,stomach,and esophagus and with advanced TNM stage in breast and esophageal cancers.PGK1 pS203 and PDHK1 pT338 were also independent predictors of short OS in liver,lung,and stomach cancer.Conclusions:The elevated expression,promoter hypomethylation,and phosphorylation of PGK1 and PDHK1 were related with disease progression and short OS in diverse types of cancer.PGK1 and PDHK1 phosphorylation may be potential prognostic biomarkers. | Fei Shao Xueying Yang Wei Wang Juhong Wang Wei Guo Xiaoli Feng Susheng Shi Qi Xue Shugeng Gao Yibo Gao Zhimin Lu Jie He | 2019 | Cancer Communications2019，39，1： | 4 |
| 5 | Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer显示文摘Small-cell lung cancer(SCLC)is the most aggressive and lethal subtype of lung cancer,for which,better understandings of its biology are urgently needed.Single-cell sequencing technologies provide an opportunity to profile individual cells within the tumor microenvironment(TME)and investigate their roles in tumorigenic processes.Here,we performed high-precision single-cell transcriptomic analysis of~5000 individual cells from primary tumors(PTs)and matched normal adjacent tissues(NATs)from 11 SCLC patients,including one patient with both PT and relapsed tumor(RT).The comparison revealed an immunosuppressive landscape of human SCLC.Malignant cells in SCLC tumors exhibited diverse states mainly related to the cell cycle,immune,and hypoxic properties.Our data also revealed the intratumor heterogeneity(ITH)of key transcription factors(TFs)in SCLC and related gene expression patterns and functions.The non-neuroendocrine(non-NE)tumors were correlated with increased inflammatory gene signatures and immune cell infiltrates in SCLC,which contributed to better responses to immune checkpoint inhibitors.These findings indicate a significant heterogeneity of human SCLC,and intensive crosstalk between cancer cells and the TME at single-cell resolution,and thus,set the stage for a better understanding of the biology of SCLC as well as for developing new therapeutics for SCLC. | Yanhua Tian Qingqing Li Zhenlin Yang Shu Zhang Jiachen Xu Zhijie Wang Hua Bai Jianchun Duan Bo Zheng Wen Li Yueli Cui Xin Wang Rui Wan Kailun Fei Jia Zhong Shugeng Gao Jie He Carl MGay Jianjun Zhang Jie Wang Fuchou Tang | 2022 | Signal Transduction and Targeted Therapy2022，7，11： | 1 |
| 6 | The SUPER reporting guideline suggested for reporting of surgical technique显示文摘Background:Existing reporting guidelines pay insufficient attention to the detail and comprehensiveness reporting of surgical technique.The Surgical techniqUe rePorting chEcklist and standaRds(SUPER)aims to address this gap by defining reporting standards for surgical technique.The SUPER guideline intends to apply to articles that encompass surgical technique in any study design,surgical discipline,and stage of surgical innovation.Methods:Following the EQUATOR(Enhancing the QUAlity and Transparency Of health Research)Network approach,16 surgeons,journal editors,and methodologists reviewed existing reporting guidelines relating to surgical technique,reviewed papers from 15 top journals,and brainstormed to draft initial items for the SUPER.The initial items were revised through a three-round Delphi survey from 21 multidisciplinary Delphi panel experts from 13 countries and regions.The final SUPER items were formed after an online consensus meeting to resolve disagreements and a three-round wording refinement by all 16 SUPER working group members and five SUPER consultants.Results:The SUPER reporting guideline includes 22 items that are considered essential for good and informative surgical technique reporting.The items are divided into six sections:background,rationale,and objectives(items 1 to 5);preoperative preparations and requirements(items 6 to 9);surgical technique details(items 10 to 15);postoperative considerations and tasks(items 16 to 19);summary and prospect(items 20 and 21);and other information(item 22).Conclusions:The SUPER reporting guideline has the potential to guide detailed,comprehensive,and transparent surgical technique reporting for surgeons.It may also assist journal editors,peer reviewers,systematic reviewers,and guideline developers in the evaluation of surgical technique papers and help practitioners to better understand and reproduce surgical technique. | Kaiping Zhang Yanfang Ma Jinlin Wu Qianling Shi Leandro Cardoso Barchi Marco Scarci Rene Horsleben Petersen Calvin S.H.Ng Steven Hochwald Ryuichi Waseda Fabio Davoli Robert Fruscio Giovanni Battista Levi Sandri Michel Gonzalez Benjamin Wei Guillaume Piessen Jianfei Shen Xianzhuo Zhang Panpan Jiao Yulong He Nuria M.Novoa Benedetta Bedetti Sebastien Gilbert Alan D.L.Sihoe Alper Toker Alfonso Fiorelli Marcelo F.Jimenez Toni Lerut Aung Y.Oo Grace S.Li Xueqin Tang Yawen Lu Hussein Elkhayat Tomaz Stupnik Tanel Laisaar Firas Abu Akar Diego Gonzalez-Rivas Zhanhao Su Bin Qiu Stephen D.Wang Yaolong Chen Shugeng Gao | 2023 | Hepatobiliary Surgery and Nutrition2023，12，4： | 0 |
| 7 | Primary intrathoracic liposarcoma:a clinical analysis of 31 cases显示文摘Dear Editor,Liposarcoma is a common soft tissue malignancy in adults.It most commonly occurs in the deep soft tis-sue of the extremities and retroperitoneum.Primary intrathoracic liposarcoma is rare,represents 2.7%of all liposarcomas[1].According to the distinct tumor loca-tions,it can be divided into mediastinal,pleural,and pulmonary liposarcomas.Most literature has reviewed the clinicopathological or molecular cytogenetic char-acteristics of mediastinal and thoracic liposarcomas[2,3].However,intrathoracic liposarcoma is poorly docu-mented because of its rarity.Complete surgical resection is thought to be the best treatment for primary intratho-racic liposarcoma,but the impact of radiotherapy and systemic therapy remains unclear.Therefore,we ana-lyzed the clinicopathological data of 31 patients with primary intrathoracic liposarcoma who were treated in the Cancer Hospital of Chinese Academy of Medical Sci-ences between October 1970 and July 2015 to explore their clinicopathologic features and treatment outcomes(Additional file 1:Table S1). | Zhixue Fu Kun Yang Xu Yang Shulan Chen Wenqing Wang Dongfu Chen Jun Zhao Zhishan Li Qinfu Feng Zongmei Zhou Luhua Wang Shugeng Gao Jun Liang | 2019 | Cancer Communications2019，39，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员